ADA 2025 20 - 23 June 2025

Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 Clinical Trials

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Obesity

Congress oral presentation

GLP-1 RA

CagriSema

PHASE 3 (RCT)